Accueil » La R&D d'Unicancer » Les publications de la R&D d'Unicancer » Les publications

Publications de la R&D d'Unicancer

2018

Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis Elvire

Elvire Pons-Tostivint et al, Annals of Surgical Oncology ; February 2019, Volume 26, Issue 2, pp 356–365

2018

Endocrine therapy or chemotherapy as first-line therapy in hormone receptorepositive HER2-negative metastatic breast cancer patients

E Jacquet et al, European Journal of Cancer 95 (2018) 93e101.

2018

Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens

Luc Cabel et al, Breast Cancer Research and TreatmentJanuary 2019, Volume 173, Issue 2, pp 397–406.

2018

Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort

Elisa Gobbini et al, European Journal of Cancer 96 (2018) 17e24.

2018

Oral contraceptive use and breast cancer risk: retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study

Lieske H. et al, JNCI Cancer Spectrum, Volume 2, Issue 2, 1 April 2018.

2018

GEMO, a national resource to study genetic modifiers of breast and ovarian cancer risk in BRCA1 and BRCA2 pathogenic variant carriers

Lesueur F. et al, Front Oncol. 2018 Oct 31;8:490. doi: 10.3389/fonc.2018.00490. eCollection 2018.

2018

The Influence of Number and Timing of Pregnancies on Breast Cancer Risk in Women with BRCA1 and BRCA2 mutations

Terry MB et al, JNCI Cancer Spectr. 2018 Dec;2(4):pky078. doi: 10.1093/jncics/pky078. Epub 2019 Mar 8.

2018

Efficacy of Anthracycline/taxane based neoadjuvant chemotherapy on Triple-Negative Breast Cancer in BRCA1 / BRCA2 mutation carriers.

Bignon L. et al, Breast J 2018 Volume24, Issue3May/June 2018Pages 269-277. Article DOI: 10.1111/tbj.12887

2018

Recommandations françaises du Groupe Génétique et Cancer pour l’analyse en panel de gènes dans les prédispositions héréditaires au cancer du sein ou de l’ovaire

Jessica Moretta et al, Bull Can 2018 oct;10 (105) doi : 10.1016/j.bulcan.2018.08.003

2018

Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)

X. Liang et al, J Hematol Oncol. 2018 Oct 11;11(1):124. doi: 10.1186/s13045-018-0670-9.